Company news from the 01/16/07 news brief

Share this article:
Genizon BioSciences announced a license and collaboration agreement with Pfizer for diagnostic rights to Genizon's discovery programs in Alzheimer's disease, attention deficit hyperactivity disorder and endometriosis. Genizon retains therapeutic rights. Under the terms of the agreement, Pfizer will pay Genizon upfront license fees and funding for research on genetic variations associated with diseases. Pfizer will also purchase an equity stake in Genizon subject to certain closing conditions. Financial terms were not disclosed. Redi-Direct Marketing has acquired New York-based Dialog Group, including the firm’s Healthcare Dialog division, a developer of relationship marketing and communication programs for the pharmaceutical industry. Financial terms of the deal were not disclosed. CMPMedica has acquired MediReach Healthcare Communications, a Shanghai, China, consultancy providing medical and pharmaceutical marketing services to multinational pharmaceutical companies across China, for an initial payment of $1.1 million and as much as $2.75 million contingent on future performance.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...